The Food and Drug Administration is trying to stop pharmaceutical companies from "gaming" the system by blocking or delaying generic competition, Reuters reported.
The agency plans a public meeting on July 18 to help it search for ways pharmaceutical companies are using its rules to block generic competition, FDA Commissioner Scott Gottlieb said in a blog post Wednesday.
"We know that sometimes our regulatory rules might be 'gamed' in ways that may delay generic drug approvals beyond the time frame the law intended, in order to reduce competition," he said in the blog post. "We are actively looking at ways our rules are being used and, in some cases, misused."
President Donald Trump and lawmakers in Congress are searching for ways to lower prescription costs.